RhumbLine Advisers
NEUP

RhumbLine Advisers’s Neuphoria Therapeutics NEUP Stock Holding History

RhumbLine Advisers’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-202
Closed -$822 – 4279
2026
Q1 		$822 Hold
202
– – ﹤0.01% 3993
2025
Q4 		$783 Buy
202
+169
+512% +$1.2K ﹤0.01% 4042
2025
Q3 		$389 Hold
33
– – ﹤0.01% 4067
2025
Q2 		$234 Sell
33
-382
-92% -$2.22K ﹤0.01% 4093
2025
Q1 		$2.39K Sell
415
-691
-62% -$3.23K ﹤0.01% 3973
2024
Q4 		$3.79K Buy
1,106
+414
+60% +$1.46K ﹤0.01% 3987
2024
Q3 		$3.61K Buy
692
+509
+278% +$4.03K ﹤0.01% 4017
2024
Q2 		$1.68K Buy
183
+74
+68% +$806 ﹤0.01% 4199
2024
Q1 		$1.34K Buy
109
+67
+160% +$883 ﹤0.01% 4122
2023
Q4 		$757 Hold
42
– – ﹤0.01% 4174
2023
Q3 		$1.36K Buy
+42
New +$905 ﹤0.01% 4154

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

RhumbLine Advisers's NEUP Position: Q2 2026 in Review

RhumbLine Advisers sold out of Neuphoria Therapeutics (NEUP) in Q2 2026, closing a stake of 202 shares — an estimated $822 sold.

RhumbLine Advisers first reported a position in NEUP in Q3 2023 and held it in 11 quarters. The position peaked at $3.79K in Q4 2024. 13 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • RhumbLine Advisers reported no remaining Neuphoria Therapeutics position as of Q2 2026 after selling out during the quarter.
  • RhumbLine Advisers sold 202 Neuphoria Therapeutics shares in Q2 2026, an estimated $822.
  • RhumbLine Advisers first reported a position in Neuphoria Therapeutics in Q3 2023 and held it in 11 quarters.
  • RhumbLine Advisers's Neuphoria Therapeutics position peaked at $3.79K in Q4 2024.
  • 13 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.